9h00 Accueil Café

9h30 – 12h00

1. **J. ROMMELAERE**: short introduction
2. **J. ROMMELAERE**: Application of natural parvoviruses to the oncolytic virotherapy of glioblastoma and pancreatic ductal adenocarcinoma
3. **A. MARCHINI**: Development of novel, more effective parvovirus-based anticancer therapies
4. **C. ENGELAND**: Oncolytic measles virus for cancer immunotherapy

12h00 – 13h30 Pause déjeuner

13h30 – 16h30 Table ronde : Perspectives de collaborations et de recherche avec les équipes du CGE

Nourdine HAMDANE, INSERM Unit 1110, Institute of Viral and Liver Diseases, University of Strasbourg
Hepatitis C virus-induced epigenetic reprogramming as driver of epatocarcinogenesis and target for cancer chemoprevention

Andres ROCA, INSERM Unit 1110, Institute of Viral and Liver Diseases, University of Strasbourg
miR-135a-5p-mediated downregulation of protein-tyrosine phosphatase delta is a candidate driver of HCV-associated hepatocarcinogenesis that acts by promoting STAT3 transcriptional activity

Jean-Luc PRETET, EA3181 Carcinogenèse Epitheliale, Université de Franche-Comté, Lab. Biologie Cellulaire et Moléculaire, CHU Beasnonçon
Régulation épigénétique de l'expression de E6 d'HPV16

Jean-François FONTENEAU, INSERM UMR892, CNRS UMR6299, Institut de Recherche en Santé de l'Université de Nantes
Antitumoral virotherapy by the oncolytic Measles virus